Pacific Biosciences of California (PACB) Stock Analysis & Winston Score

Pacific Biosciences (PacBio) makes DNA sequencing machines used by scientists and researchers. Its main products are long-read sequencing instruments, like the Revio and Onso systems, which read genetic code in longer stretches than most competing machines. Customers include universities, government research labs, hospitals, and pharmaceutical companies trying to better understand genes and diseases. PacBio earns money by selling its sequencing instruments and then generating recurring revenue from consumables — the chemical reagents and supplies customers must keep buying to run each experiment. The company operates primarily in the United States but sells globally, competing against much larger rivals like Illumina and Oxford Nanopore. With a market cap around $400 million and an operating margin of roughly negative 100%, PacBio is spending far more than it earns, making its path to profitability the central risk investors watch. Growing adoption of long-read sequencing in clinical and research settings is the key growth driver, but the company must scale revenue significantly before cash runs out.